REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Licensees…More are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.
REPORT RATINGS
4.8 / 5.0 (193)
Regenxbio Inc. reports have an aggregate usefulness score of 4.8 based on 193 reviews.